Loading data for PCSA — first visit, this takes a few seconds.
Processa Pharmaceuticals ... (PCSA)
NasdaqCM: PCSA
· Real-Time Price · USD
2.08
-0.07 (-3.26%)
At close: Aug 24, 2026, 7:20 PM
The price, the headline numbers and the latest news, in one place.
Processa Pharmaceuticals Inc. (PCSA) Stock Price, Analysis & Data
-3.26% (1D)
No data available
| Bid | 0.05 |
| Market Cap | 6.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.44M |
| 0.96 | |
| 0.65 | |
| 3.35 | |
| -0.58 | |
| P/B (ttm) | 2.30 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.62 |
| Volume | 72,722 |
| Avg. Volume (20D) | 251,259 |
| Open | 2.21 |
| Previous Close | 2.15 |
| Day's Range | 2.00 - 2.21 |
| 52-Week Range | 1.67 - 14.25 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PCSA
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS642...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 7, 2014
Employees 12
Stock Exchange NasdaqCM
Ticker Symbol PCSA
Financial Performance
In 2025, Processa Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -13.56M, an increase of 14.46%.
Financial StatementsEarnings Surprise
Processa Pharmaceuticals has released their quarterly earnings on Nov 6, 2025:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.75 exceeds estimates by 0.25, with 93.20% YoY growth.
